- Home
- NETD vs EDIT Comparison
NETD vs EDIT Comparison
Compare NETD & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NETD
- EDIT
- Stock Information
- Founded
- NETD 2023
- EDIT 2013
- Country
- NETD United States
- EDIT United States
- Employees
- NETD N/A
- EDIT N/A
- Industry
- NETD
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NETD
- EDIT Health Care
- Exchange
- NETD Nasdaq
- EDIT Nasdaq
- Market Cap
- NETD 241.3M
- EDIT 263.7M
- IPO Year
- NETD 2023
- EDIT 2016
- Fundamental
- Price
- NETD $11.29
- EDIT $2.76
- Analyst Decision
- NETD
- EDIT Buy
- Analyst Count
- NETD 0
- EDIT 12
- Target Price
- NETD N/A
- EDIT $5.40
- AVG Volume (30 Days)
- NETD 2.0K
- EDIT 1.8M
- Earning Date
- NETD 01-01-0001
- EDIT 11-03-2025
- Dividend Yield
- NETD N/A
- EDIT N/A
- EPS Growth
- NETD N/A
- EDIT N/A
- EPS
- NETD 0.20
- EDIT N/A
- Revenue
- NETD N/A
- EDIT $38,901,000.00
- Revenue This Year
- NETD N/A
- EDIT N/A
- Revenue Next Year
- NETD N/A
- EDIT N/A
- P/E Ratio
- NETD $55.10
- EDIT N/A
- Revenue Growth
- NETD N/A
- EDIT N/A
- 52 Week Low
- NETD $10.58
- EDIT $0.91
- 52 Week High
- NETD $11.47
- EDIT $4.12
- Technical
- Relative Strength Index (RSI)
- NETD 58.28
- EDIT 54.04
- Support Level
- NETD $11.13
- EDIT $2.39
- Resistance Level
- NETD $11.24
- EDIT $2.72
- Average True Range (ATR)
- NETD 0.04
- EDIT 0.18
- MACD
- NETD -0.00
- EDIT -0.01
- Stochastic Oscillator
- NETD 88.89
- EDIT 53.62
About NETD Nabors Energy Transition Corp. II
Nabors Energy Transition Corp II is a blank check company.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.